With 46,700 avg volume, 0 days are for Auxilio INC. The SI to Akebia Therapeutics Incorporated's float is 14.37%.
The stock increased 3.00% or GBX 4.89 on August 16, reaching GBX 167.9. It has outperformed by 76.24% the S&P500.
Since June 5, 2017, it had 0 buys, and 1 insider sale for $10,545 activity. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Therefore 14% are positive.
Other research analysts have also recently issued reports about the company. Deutsche Bank downgraded the stock to "Hold" rating in Monday, January 11 report. The rating was maintained by H.C. Wainwright with "Buy" on Tuesday, December 15. The ex-dividend date is Wednesday, August 9th. The rating was maintained by Liberum Capital on Tuesday, November 17 with "Buy". The firm has "Overweight" rating by JP Morgan given on Friday, April 28. The rating was maintained by JP Morgan on Tuesday, March 21 with "Neutral".
The stock increased +1.58% (+3.00) during the last trading session, reaching 0.00 and roughly 4087 shares were bought or sold by traders.
Investors sentiment increased to 1.41 in Q4 2016. Its up 0.02, from 0.86 in 2016Q3. 18 funds opened positions while 33 raised stakes. Jpmorgan Chase & reported 4.87M shares.
Krensavage Asset Management Llc holds 5.21% of its portfolio in CONMED Corporation for 328,677 shares. Moreover, Bridgewater Limited Partnership has 0.04% invested in Intu Properties PLC (LON:INTU). Renaissance holds 0.01% or 174,284 shares in its portfolio. Blackrock Management Ltd Liability stated it has 0% in Akebia Therapeutics Inc (NASDAQ:AKBA). The Company's divisions are the medical market and the veterinary market. The Firm focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). The latest broker reports which are now outstanding on Wednesday 16th of August state 1 analyst has a rating of "strong buy", 0 analysts "buy", 3 analysts "neutral", 0 analysts "sell" and 1 analysts "strong sell". Therefore 26% are positive. GKN has a 52 week low of GBX 295.20 and a 52 week high of GBX 379.30. The company has an average rating of "Buy" and a consensus target price of GBX 281.67 ($3.66). Man Group PLC had 151 analyst reports since July 24, 2015 according to SRatingsIntel. (NYSE:DG) rating on Friday, May 27. The rating was maintained by Peel Hunt on Wednesday, March 9 with "Buy".
ILLEGAL ACTIVITY NOTICE: "GKN plc (LON:GKN) Stock Rating Reaffirmed by Beaufort Securities" was originally reported by BBNS and is the sole property of of BBNS. The firm earned "Outperform" rating on Monday, October 19 by Credit Suisse. The stock of Staffline Group Plc (LON:STAF) earned "Buy" rating by FinnCap on Tuesday, July 5. The firm has "Buy" rating by Sterne Agee CRT given on Tuesday, July 21. Liberum Capital reaffirmed a "sell" rating and set a GBX 300 ($3.89) price objective on shares of GKN plc in a research note on Friday, April 7th. Argus Research upgraded the stock to "Buy" rating in Monday, June 12 report.
About 1.44M shares traded. Bodycote PLC (LON:BOY) has 0.00% since August 16, 2016 and is. It has underperformed by 16.70% the S&P500.
Big Yellow Group PLC is a United Kingdom-based company, which is engaged in the provision of self-storage and related services. The company's market cap is GBX 2.36 billion. The Firm has two divisions: Staffing Services, which includes the provision of temporary staff to customers, and PeoplePlus, which includes the provision of welfare to work and other training services.